World's First CAR-T Therapy Kymriah Approved for Clinical Treatment in China

On October 30, CDE's official website updated a list of clinically implied licenses, including Novartis's CAR-T therapy star drug CTL019 (Tisagenlecleucel), which has recurrent or incurable invasive B-cell non-Hodgham lymphomaAugust 30, 2017, CTL019 (business name: Kymriah) was approved by the U.SFDA as the first marketed CAR-T drug for the treatment of patients under the age of 25 with B-cell precursor acute lymphoid leukemia (ALL) who are indifficult yMay 1, 2018, Kymriah was approved for a second indication to treat adult patients with recurrent or refractory diffuse large B-cell lymphoma (DLBCL) (previously treated with two or more systems)Insight's Global New Drug Database shows that Kymriah's adaptations such as non-Hodgkin's lymphoma, follicle lymphoma, and multiple myeloma are also undergoing clinical trials, with the country's approved non-Hodgkin's lymphoma indications progressing to stage 3 clinical lynows abroadOctober 18, 2017, Kite Pharma's CAR-T product Yescarta (axicabagene ciloleucel, KTE-C19) is approved by the U.SFDA for the treatment of adult recurrent or refractory large B-cell lymphomaYescarta is the world's second approved CAR-T product and the first CAR-T product to treat non-Hodgkin's lymphomacurrently, neither CAR-T product has been approved in the country, insight database shows (https://db.dxy.cn), there are eight domestic clinical CAR-T companies, but the fastest progress has entered the phase 2 clinical phaseIn March 2018, Nanjing Legendary Biotech Co., Ltdofficially received the original CFDA approval for the original CCAR-B38M CAR-T clinical trial for self-transfusion, which is also the first CAR-T therapy clinical trial in Chinaaccording to the, 12 companies have approved CAR-T therapies for clinical use (including Novartis's CTL019), and 25 companies are reporting CAR-T therapiesThe global CAR-T cell therapy market has been valued at $167 million by 2018, according to research dataAccording to The Coherent Market Insights, the global CAR-T cell therapy market value will grow at an average annual CAGR of 46.1% over the period 2018-2028However, with the advancement of China's CAR-T-related policies and the strengthening of research and development, more and more enterprises are flocking to the CAR-T industry market, China is expected to bend overtaking in the next short period of time, occupying a large part of the global market share.